NCT02420977View on ClinicalTrials.gov

Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 6, 2018

Primary Completion Date

March 1, 2024

Study Completion Date

March 1, 2025

Conditions
Advanced Prostate Cancer
Interventions
DRUG

Pelvic DCFPyL PET-MRI fusion or PET/MRI

"* Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months of ADT~* Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months"

Trial Locations (1)

21287

Curtiland Deville, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT02420977 - Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer | Biotech Hunter | Biotech Hunter